Interrelations between plasma caffeine concentrations and neurobehavioural effects in healthy volunteers: Model analysis using NONMEM

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 5-6, 2010, Pages 316-330

  Seng, Kok Yong ^a   Teo, Wei Ling Grace ^a,b   Fun, Chiok Yuen David ^a   Law, Yu Li Lydia ^a,c   Lim, Chin Leong ^a  

^a DSO NATIONAL LABORATORIES   (Singapore)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

^c SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

Author keywords

Caffeine; Mixed effects model; Neurobehavioural tests; NONMEM; Pharmacokinetics and pharmacodynamics

Indexed keywords

CAFFEINE; CENTRAL STIMULANT AGENT;

ADULT; ARTICLE; BOOTSTRAPPING; CHINESE; CLINICAL TRIAL; COGNITION; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; MALE; MORNING DOSAGE; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; SACCADIC EYE MOVEMENT; SCORING SYSTEM; SWEDISH PERFORMANCE EVALUATION SYSTEM; VELOCITY; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DRUG EFFECTS; NONLINEAR SYSTEM; PSYCHOLOGY; TIME;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MALE; NONLINEAR DYNAMICS; PSYCHOMOTOR PERFORMANCE; TIME FACTORS;

EID: 77955673044     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.714     Document Type: Article

References (39)

1. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special references to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
2. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978; 24: 40-45.
3. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 1981; 21: 45-52.
4. Blanchard J, Sawers ST. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm 1983; 11: 109-126.
5. Joeres R, Klinker H, Heusler H, Epping J, Zilly W, Richter E. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 1988; 8: 575-579.
6. Csajka C, Haller CA, Benowitz NL, Verotta D. Mechanistic pharmacokinetic modeling of ephedrine, norephedrine and caffeine in healthy subjects. Br J Clin Pharmacol 2005; 59: 335-345.
7. Seng KY, Fun CY, Law YL, Lim WM, Fan W, Lim CL. Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. J Clin Pharm Ther 2009; 34: 103-114.
8. Quinlan PT, Lane J, Moore KL, Aspen J, Rycroft JA, O'Brien DC. The acute physiological and mood effects of tea and coffee: the role of caffeine level. Pharmacol Biochem Behav 2000; 66: 19-28.
9. Mackay M, Tiplady B, Scholey AB. Interactions between alcohol and caffeine in relation to psychomotor speed and accuracy. Hum Psychopharmacol Clin Exp 2002; 17: 151-156.
10. Rogers PJ, Martin J, Smith C, Heatherley SV, Smit HJ. Absence of reinforcing, mood and psychomotor performance effects of caffeine in habitual non-consumers of caffeine. Psychopharmacology 2003; 167: 54-62.
11. Childs E, de Wit H. Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. Exp Clin Psychopharmacol 2008; 16: 13-21.
12. Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol 2008; 77: 113-122.
13. Shi J, Benowitz NL, Denaro CP, Sheiner LB. Pharmacokinetic- pharmacodynamic modelling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 1993; 53: 6-14.
14. Kaplan GB, Greenblatt DJ, Ehrenberg BL, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 1997; 37: 693-703.
15. Bryant CA, Farmer A, Tiplady B, et al. Psychomotor performance: investigating the dose-response relationship for caffeine and theophylline in elderly volunteers. Eur J Clin Pharmacol 1998; 54: 309-313.
16. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol 1996; 34: 119-129.
17. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-175.
18. Iregren A, Gamberale F, Kjellberg A. SPES: A psychological test system to diagnose environmental hazards. Neurotoxicol Teratol 1996; 18: 485-491.
19. Bocca ML, Denise P. Total sleep deprivation effect on disengagement of spatial attention as assessed by saccadic eye movements. Clin Neurophysiol 2006; 117: 894-899.
20. Schleicher R, Galley N, Briest S, Galley L. Blinks and saccades as indicators of fatigue in sleepiness warnings: looking tired? Ergonomics 2009; 51: 982-1010.
21. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur J Cancer 1998; 34: 92-97.
22. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother 2004; 38: 2136-2144.
23. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143-166.
24. Jensen ML, Sjøgren P, Upton RN, et al. Pharmacokinetic- pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic Clin Pharmacol Toxicol 2008; 103: 94-101.
25. Yafune A, Ishiguro M. Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: a use of bootstrap standard error. Stat Med 1999; 18: 581-599.
26. Holford N. Wings for NONMEM: Wings version 615 program free download [online]. Available from URL: http://wfn.sourceforge.net/index.html [Accessed 1 October 2009].
27. Smith AP, Brockman P, Flynn R, Maben A, Thomas M. Investigation of the effects of coffee on alertness and performance and mood during the day and night. Neuropsychobiology 1993; 27: 217-223.
28. Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. Psychopharmacology (Berl) 2002; 164: 250-261.
29. James JE. Does caffeine enhance or merely restore degraded psychomotor performance? Neuropsychobiology 1994; 30: 124-125.
30. Lott DC, Kim SJ, Cook Jr EH, de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005; 30: 602-609.
31. Holford NH, Peace LB. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 1992; 89: 11471-11475.
32. Carrillo JA, Benitez J. Clinically significant pharma-cokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39: 127-153.
33. Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 1986; 22: 183-186.
34. 2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1985; 330: 212-221. (Pubitemid 15003581)
35. Lowenstein O, Loewenfeld I. Types of central autonomic innervation and fatigue. Arch Neurol Psychiatry 1951; 66: 581-599.
36. Bennett CL, Petros TV, Johnson M, Ferraro FR. Individual differences in the influence of time of day on executive functions. Am J Psychol 2008; 121: 349-361.
37. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol 2002; 40: 1243-1255.
38. Fine BJ, Kobrick JL, Lieberman HR, Marlowe B, Riley RH, Tharion WJ. Effects of caffeine or diphenhydramine on visual vigilance. Psychopharmacology (Berl) 1994; 114: 233-238.
39. Smit HJ, Rogers PJ. Effects of low doses of caffeine on cognitive performance, mood, and thirst in low and high caffeine consumers. Psychopharmacology 2000; 152: 167-173.